Table 4.
Correlation between expression of AQP9 and DVL2, and clinicopathological features of patients with CRC
| Variable | AQP9LDVL2L | AQP9HDVL2H | P-value |
|---|---|---|---|
| Sex | 0.035* | ||
| Male | 26 (68.4%) | 27 (46.6%) | |
| Female | 12 (31.6%) | 31 (53.4%) | |
| Median age (years) | 0.112 | ||
| <66 | 20 (52.6%) | 21 (36.2%) | |
| ≥66 | 18 (47.4%) | 37 (63.8%) | |
| Clinical stage | <0.001*** | ||
| I–II | 32 (84.2%) | 28 (48.3%) | |
| III–IV | 6 (15.8%) | 30 (51.7%) | |
| pT status | 0.058 | ||
| T1–T2 | 4 (10.5%) | 1 (1.7%) | |
| T3–T4 | 34 (89.5%) | 57 (98.3%) | |
| pN status | 0.002** | ||
| N0 | 32 (84.2%) | 31 (53.4%) | |
| N1–N2 | 6 (15.8%) | 27 (46.6%) | |
| pM status | 0.083 | ||
| M0 | 36 (94.7%) | 48 (82.8%) | |
| M1 | 2 (5.3%) | 10 (17.2%) | |
| Disease progression | 0.017* | ||
| No | 30 (78.9%) | 32 (55.2%) | |
| Yes | 8 (21.1%) | 26 (44.8%) |
*
P < 0.05;
**
P < 0.01;
***
P < 0.001.
CRC, colorectal cancer; T, tumor; N, node; M, metastasis.